Literature DB >> 21917862

Long-term impact of GH treatment during childhood on body composition and fat distribution in young adults born SGA.

P E Breukhoven1, G F Kerkhof, M van Dijk, A C S Hokken-Koelega.   

Abstract

CONTEXT: GH treatment of short children born small for gestational age (SGA) results in a decline in fat mass (FM) and an increase in lean body mass (LBM). It is, however, unknown whether these changes persist into adulthood.
OBJECTIVE: Our objective was to assess the long-term impact of GH treatment during childhood on body composition and fat distribution. PATIENTS AND
DESIGN: A total of 377 young adults participated in this cross-sectional study: 59 previously GH-treated young SGA adults compared to 52 untreated SGA adults with short stature (SGA-S), 161 SGA adults with spontaneous catch-up growth (SGA-CU), and 105 healthy normal-statured controls born appropriate for gestational age (AGA). OUTCOME MEASURES: Body composition and fat distribution were determined by dual-energy x-ray absorptiometry.
RESULTS: Mean (SD) duration of GH treatment was 7.7 (2.4) yr and period after discontinuation 6.8 (1.8) yr. FM, fat distribution, and LBM of GH-treated SGA adults were not significantly different from that of untreated SGA-S adults. GH-treated SGA adults also had a similar FM and fat distribution as SGA-CU adults but a lower LBM. All SGA subgroups had a lower LBM and tended to have a higher FM than healthy AGA controls.
CONCLUSION: Body composition and fat distribution of previously GH-treated SGA adults was similar to that of untreated SGA-S adults. GH-induced catch-up growth has no unfavorable effect on FM and fat distribution compared with spontaneous catch-up growth. However, our study shows that SGA adults in general may have a different body composition than healthy AGA controls.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917862     DOI: 10.1210/jc.2011-1658

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Developmental Programming of Body Composition: Update on Evidence and Mechanisms.

Authors:  Elvira Isganaitis
Journal:  Curr Diab Rep       Date:  2019-07-20       Impact factor: 4.810

Review 2.  The Rationale for Growth Hormone Therapy in Children with Short Stature.

Authors:  Annalisa Deodati; Stefano Cianfarani
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27

3.  Effects of size at birth, childhood growth patterns and growth hormone treatment on leukocyte telomere length.

Authors:  Carolina C J Smeets; Veryan Codd; Matthew Denniff; Nilesh J Samani; Anita C S Hokken-Koelega
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

Review 4.  Achieving Optimal Short- and Long-term Responses to Paediatric Growth Hormone Therapy

Authors:  Jan M. Wit; Asma Deeb; Bassam Bin-Abbas; Angham Al Mutair; Ekaterina Koledova; Martin O. Savage
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-07-09

5.  Evidence for Accelerated Biological Aging in Young Adults with Prader-Willi Syndrome.

Authors:  Stephany H Donze; Veryan Codd; Layla Damen; Wesley J Goedegebuure; Matthew Denniff; Nilesh J Samani; Janiëlle A E M van der Velden; Anita C S Hokken-Koelega
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

6.  Height and body mass index in molecularly confirmed Silver-Russell syndrome and the long-term effects of growth hormone treatment.

Authors:  Oluwakemi Lokulo-Sodipe; Eloïse Giabicani; Ana P M Canton; Nawfel Ferrand; Jenny Child; Emma L Wakeling; Gerhard Binder; Irène Netchine; Deborah J G Mackay; Hazel M Inskip; Christopher D Byrne; I Karen Temple; Justin H Davies
Journal:  Clin Endocrinol (Oxf)       Date:  2022-03-21       Impact factor: 3.523

7.  Adiposity in Children Born Small for Gestational Age Is Associated With β-Cell Function, Genetic Variants for Insulin Resistance, and Response to Growth Hormone Treatment.

Authors:  Ajay Thankamony; Rikke Beck Jensen; Susan M O'Connell; Felix Day; Jeremy Kirk; Malcolm Donaldson; Sten A Ivarsson; Olle Söder; Edna Roche; Hilary Hoey; Ken K Ong; David B Dunger; Anders Juul
Journal:  J Clin Endocrinol Metab       Date:  2015-11-20       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.